The companies have presented positive Phase II data during an oral session at IDWeek 2024, in Los Angeles, US.

GILD and partner MRK advance novel investigational combination regimen, a weekly oral HIV treatment, to phase III.

On Saturday, Gilead Sciences, Inc. (NASDAQ:GILD) and Merck & Co. Inc. (NYSE:MRK) revealed new results from a Phase 2 clinical ...

Those include Sunlenca, which is approved for resistant HIV as a twice-yearly injection after an initial oral regimen, and ...

Gilead and Merck & Co. have guided their once-weekly HIV combination therapy past another milestone, linking the cocktail to ...

US drugmakers Gilead Sciences (Nasdaq: GILD) and Merck & Co (NYSE: MRK) have announced new results from a Phase II clinical ...

Gilead Sciences (GILD) and Merck (MRK) announced new results from a Phase 2 clinical study evaluating the investigational combination of ...

Gilead Sciences Inc. (GILD) and Merck & Co Inc.(MRK) announced new results from a Phase 2 clinical study evaluating the ...

Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today ...

Sep. 25, 2024 — Almost everyone knows about HIV. Fewer people know about its relative, HTLV-1. However, HTLV-1 can cause serious illnesses, including cancer. To develop ways to combat this virus ...

A 59-year-old Ridgetown woman faces a trafficking charge after a drug seizure Tuesday night. Approximately $36,000 worth of suspected cocaine and oxycodone were seized for analysis after the raid ...

This advertisement has not loaded yet, but your article continues below. Provincial police threw cold water on a Brockville man’s romantic plans Sunday when he was stopped on Highway 416 due to ...